Brain cancer patient treated with off-label drug frets over costs when insurance coverage stops in April 2023

Brain cancer patient Zhang Chang Hua (left) seeking medical advice from Dr Daniel Chan, senior consultant at Icon Cancer Centre. ST PHOTO: DESMOND WEE
New: Gift this subscriber-only story to your friends and family

SINGAPORE - Mr Zhang Chang Hua is 42 years old and works in regional customer service for a multinational company. He and his wife, a nurse, have two sons in secondary school. He also has brain cancer.

His cancer has been under control for the past year with a drug used off-label - meaning the drug has not been approved for this particular type of cancer. With this drug, his oncologist says he has many good years ahead of him.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's WhatsApp Channel and get the latest news and must-reads.